| Popis: |
Background The reprogramming of lipid metabolism in tumor cells has led to a new focus on the study of lipid metabolism, which provides raw materials and energy for tumor cell growth and also serves as an intracellular second messenger involved in cell growth and proliferation. There is increasing evidence that fatty acid synthase( FASN), a key enzyme in lipid metabolism, is overexpressed in many cancers in association with cancer progression. However, there is no systematic pan-cancer analysis of FASN. Methods We used the available public databases TIMER2.0, GEPIA2, cBioPortal, UALCAN, and TCGA (The Cancer Genome Atlas) to analyze FASN expression and its correlation with prognosis, clinicopathological staging, immune cell infiltration, and potential mechanisms of carcinogenesis in a variety of cancers. Results The expression of FASN was significantly increased in a variety of tumor tissues compared with adjacent normal tissues, and its expression was significantly correlated with the prognosis of tumor cases. The present study also showed that genetic alterations in FASN were also correlated with the prognosis of some cancers. We also found that FASN phosphorylation at S724 S725, S1174, S1411, and T2204 was significantly decreased in breast cancer, and in renal clear cell carcinoma FASN phosphorylation at S207, S2198 was also significantly decreased, but in lung adenocarcinoma, FASN phosphorylation at S207 was significantly increased. In addition, FASN expression in several tumors was positively correlated with cancer-associated fibroblasts, and FASN was involved in the co-expression of genes related to fatty acid metabolism. Conclusion This pan-cancer analysis identified significant upregulation of FASN in various cancers and correlated with poor prognosis and immune infiltration in a variety of cancers, and provided further insight into the mechanisms of FASN's role in cancer progression. |
